VIGL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VIGL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Vigil Neuroscience has a Altman Z-Score of N/A, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Vigil Neuroscience's Altman Z-Score or its related term are showing as below:
The historical data trend for Vigil Neuroscience's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vigil Neuroscience Annual Data | |||||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||
Altman Z-Score | - | - | - | - | - |
Vigil Neuroscience Quarterly Data | ||||||||||||||||||
Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Altman Z-Score | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Vigil Neuroscience's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vigil Neuroscience's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Vigil Neuroscience's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Vigil Neuroscience's Altman Z-Score for today is calculated with this formula:
Z | = | 1.2 | * | X1 | + | 1.4 | * | X2 | + | 3.3 | * | X3 | + | 0.6 | * | X4 | + | 1.0 | * | X5 |
= | 1.2 | * | 0.5645 | + | 1.4 | * | -2.6088 | + | 3.3 | * | -0.7159 | + | 0.6 | * | 1.793 | + | 1.0 | * | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Trailing Twelve Months (TTM) ended in Dec. 2024:
Total Assets was $117.69 Mil.
Total Current Assets was $100.58 Mil.
Total Current Liabilities was $34.15 Mil.
Retained Earnings was $-307.03 Mil.
Pre-Tax Income was -23.831 + -19.258 + -21.227 + -19.94 = $-84.26 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Market Cap (Today) was $82.58 Mil.
Total Liabilities was $46.06 Mil.
* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.
X1 | = | Working Capital | / | Total Assets |
= | (Total Current Assets - Total Current Liabilities) | / | Total Assets | |
= | (100.584 - 34.147) | / | 117.691 | |
= | 0.5645 |
X2 | = | Retained Earnings | / | Total Assets |
= | -307.028 | / | 117.691 | |
= | -2.6088 |
X3 | = | Earnings Before Interest and Taxes | / | Total Assets |
= | (Pre-Tax Income - Interest Expense) | / | Total Assets | |
= | (-84.256 - 0) | / | 117.691 | |
= | -0.7159 |
X4 | = | Market Value Equity | / | Book Value of Total Liabilities |
= | Market Cap | / | Total Liabilities | |
= | 82.577 | / | 46.056 | |
= | 1.793 |
X5 | = | Revenue | / | Total Assets |
= | 0 | / | 117.691 | |
= | 0 |
The zones of discrimination were as such:
Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones
Vigil Neuroscience has a Altman Z-Score of N/A indicating it is in Distress Zones.
Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.
Vigil Neuroscience (NAS:VIGL) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Read more about Altman Z-Score and the original research.
Be Aware
Altman Z-Score does not apply to financial companies.
Thank you for viewing the detailed overview of Vigil Neuroscience's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Ivana Magovcevic-liebisch | director, officer: President and CEO | 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
Budd Haeberlein Samantha L. | director | VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472 |
Christopher Silber | officer: Chief Medical Officer | C/O VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472 |
Gray David L. F. | officer: Chief Science Officer | VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472 |
Spyridon Papapetropoulos | officer: Chief Medical Officer | C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608 |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
Clay Thorp | director | C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701 |
Evan Thackaberry | officer: SVP, Head of Early Development | VIGIL NEUROSCIENCE, INC., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Jennifer Lynn Ziolkowski | officer: Chief Financial Officer | C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139 |
Christopher Verni | officer: General Counsel | VIGIL NEUROSCIENCE, INC., 1 BROADWAY, 7TH FLOOR, SUITE 07-300, CAMBRIDGE MA 02142 |
Mary Thistle | director | C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142 |
Atlas Venture Fund Xii, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Bruce Booth | director | 890 WINTER STREET, SUITE 320, WALTHAM MA 02451 |
Stefan Vitorovic | director | C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142 |
Northpond Ventures Gp, Llc | 10 percent owner | 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814 |
From GuruFocus
By GuruFocus News • 12-20-2024
By PRNewswire • 07-08-2024
By Marketwired • 05-30-2024
By Marketwired • 08-01-2024
By Marketwired • 01-23-2025
By Marketwired • 11-12-2024
By GuruFocus News • 11-14-2024
By PRNewswire • 10-09-2024
By Marketwired • 09-16-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.